(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Beijing accused the United States on Friday of exerting "tariff pressure and blackmail" after President Donald Trump's latest ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...

Sanofi and Regeneron’s blockbuster biologic Dupixent ... in elderly adults – as the immune system mistakenly attacks proteins in the skin’s basement membrane, leading to inflammation ...

It works by blocking certain proteins in the immune system that trigger inflammation and helps to reduce symptoms, including itching, sinus congestion and breathing difficulties. While Regeneron ...